Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Shareholder Meeting (November 2006)
15 slides from Optiscan Imaging's shareholder meeting presentation, Nov 8, 2006
Slide 1: AGM 2006
AGM 2006 (ptiscer «Full scale production sales (lease materon4.March 2006 * 47 instruments sold to. 30.June 2006 * Accelerating Pentax marketing and sales “ DDW symposium “ Live demonstrations at medical meetings Brochure
Slide 2: FIVE1 and year highlights
*. “FIVE” = Fluorescent in Vives Endomicroscope..-c% ? ° “1” because of its simplicity of use * Target market. segmiéhits are: " Drug development research " Doctors combining clinical and pre-clinical research * Unique in-vivo research capabilities * Full Optiscan production " Second endo-microscope
Slide 3: Product platforms and financial position
Pentax GI non- Isc 1000 invasive iagnosis Optiscan Preclinical FIVE 1 research Rigid Endo- = ‘intra— microscopes °Pefative diagnosis Second A : generation applications & markets Broncho- Lung non- scope invasive diagnosis Multi Photon Deeper System ISSUE : (Opti imaging Financial position at dynes *
Slide 4: Exceptional efficacy across applications
(pti The global leader in microscopic imaging technologies for medical markets Exceptional efficacy: data were obtained in, an increased number. of app ications. Study Focus Sensitivity... Specificity | Accuracy Neoplasia in ulcerative colitis 94.7% 3 4,87 8% Diagnosis of Barrett's esophagus 98.8% 9
Slide 5: Solid progress in trial outcomes
Solid progress in trial outcomes * Efficacy Data/Applications ; y * At June 2005, 5 applications with excellent. t efficacy * At June 2006, this had grown to 9-appilications * 2 Clinical trials initiated for rigid endomicroscopes * Publications * 41 original clinical articles * 8 reviews relating da
Slide 6: Training in Endomicroscopy
Training in Endomicroscopy * Training fe -_ * European training centré establistied (Mainz, Germany) * >47 visiting doctors trained so far in Calendar 2006 * Johns Hopkins Hospital established-as*Key training site * Utilisation * Initial users utilised endomicroscopy in one or two applications with
Slide 7: Pentax ISC 1000 adoption path
PENTAX Leading Hospita Isc 1000 been Keen. Early © = Contre of Excellence (training) Build “Sales Release «Mktg Claims, Awareness (research Keaily adopter) litt sales, ——>__ Single-Centre, —=«=«sMulti-Centre. Trials 1 Trials Reimbursement & Mainstream Sales:
Slide 8: Reimbursement & Mainstream Sales
Relmbursement & Mainstream Sales “Market Pilot Single enue = Multi Centre Research Trials ‘Trials. ' Trials > uc > Barrett's > Colorectal neoplasm senses eeweenennenwneneunen: > Gastric Cancer "Mita Claims, _lifsales Reimbursement & Mainstream Sales * R.pylori-GC * Coeliac's © MiCKO-COLItIS ---1ewee
Slide 9: Clinical Trials for Rigid Endomicroscopes
Clinical Trials for Rigid Endom os¢opes Mainz University Hospital {Gemmany) “_ Single-Centre “Multi-Cenire Triste Trials Pancreatic Ca Liver disease Endometriosis Other ~
Slide 10: Summary
Summary * Reimbursement & Mainstream Sales “Market Pilot Single-Centre. |= MulltiCentre Research Trials Tals Tale > Flex Class 1 > PD FlOX CRASS Up oeewenee cane nee weneenenrenanennan > Rigid steteannranevons > pti: The global leader in microscopic imaging technologies for medical markets
Slide 11: Pentax ISC 1000 and FIVE1 Outlook
PENTAX 1s¢ 1000 ou J ISC 1000 * Flagship technology * Strong sales in Europe * Doctor training at Mainz, Germany a _ key success factor * USA behind, but rapidly catching up * Johns Hopkins as key training centre * Strong Pentax orders but with softening forecast into next year * Visibility and feed
Slide 12: Clinical pilot trials and production expansion
* Clinical pilot trials commenced in « Sydney — Open surgery « Germany — Mini laparoscopy * First two end points completed « Sheath design for sterility viable « Efficient clinical workflow established * 6 potential partners in discussion under CDA * Continue to build value ahead of partnering deal(
Slide 13: Financial Outlook
Financial Outi Six months sales to December 2006 guidance “ Sales revenue similar to 2°4 six: months: of 2006 ” Expect shipment of 45 - 50 systems — " Backlog due to lost throughput in redevelopirient, “but expected to be recovered by end January Six months to December 2006 : expect smail loss to br
Slide 14: AGM resolution voting results
Optiscan Imaging Annual General Meeti Q mo * Resolution 1 : Remuneration Rep j For 26,660,385 86.88% Against 276,743 0.90% Open 3,705,302 12.08% Abstain 43,090 0.14% Optiscan Imaging Limite Annual General Meeting 2006 ‘aU * Resolution 2 : Re-election of Peter Delaney For 27,044,133 88.13% Against 8,
Slide 15: (pti
(pti The global leader in microscopic imaging technologies for medical markets 15
Optiscan Imaging — Shareholder Meeting (November 2006) on 6ix